Valence ロゴ
人気
ログイン
Loading data for SLN — first visit, this takes a few seconds.

ウォッチリストに追加

Silence Therapeutics

NasdaqGM: SLN · リアルタイム株価 · USD
13.61
-0.49 (-3.48%)
終値時点： Aug 19, 2026, 8:00 PM

Silence Therapeutics (SLN) Stock Price, Analysis & Data

-3.48%

データがありません

買気配n/a
時価総額845.92M
売上高（TTM）615K
純利益（TTM）-59.95M
ベータ1.41
EPS（TTM）-1.29
PER（TTM）n/a
予想PER-17.79
PBR（TTM）10.32
PSR（TTM）1375.47
Earnings DateNov 5, 2026
売気配n/a
出来高976,134
平均出来高（20日）920,217
始値14.59
前日終値14.10
当日レンジ13.47 - 14.59
52週レンジ4.19 - 17.58
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

SLNについて

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN36...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Sep 8, 2020
従業員数 88
上場取引所 NasdaqGM
ティッカー SLN
ウェブサイト https://www.silence-therapeutics.com
企業情報の全文

業績

2025年のSilence Therapeuticsの売上高は559Kで、前年の43.26Mから-98.71%の減少でした。 利益は-88.61Mで、95.57%の増加でした。

財務諸表

決算サプライズ

Silence TherapeuticsはAug 10, 2026に四半期決算を発表しました：
  • 売上高は $422K で、予想を下回りました $0, うち 197.18% の前年比増加にあたります.
  • EPSは -0.27 で、予想を下回りました -0.16, うち 50.91% の前年比増加にあたります.

    • 次回決算発表

    Silence Therapeuticsの決算発表予定日は Nov 5, 2026, 寄り付き前の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    1週間前 · MT Newswires

    European Equities Traded in the US Rise in Thursday Trading

    European equities traded in the US as American depositary receipts were higher late Thursday morning

    news image

    1週間前 · Zacks

    Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

    The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionabl...

    news image

    1週間前 · MT Newswires

    European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

    European equities traded in the US as American depositary receipts were tracking higher late Tuesday

    news image

    1週間前 · MT Newswires

    Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

    Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activ

    news image

    1週間前 · MarketBeat

    Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

    Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its prim...

    2ページ中1ページ